Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy‐induced peripheral neuropathy: A mediation effect analysis

Abstract

Chemotherapy‐induced peripheral neuropathy (CIPN) with restriction of daily activity (RDA) was common consequence of oxaliplatin‐based chemotherapy in colorectal cancer patients. CIPN with RDA and negative mood may impact the quality of life (QoL). However, the relationships among RDA, mood, and QoL remain unclear. This was a cross‐sectional relative study in which four instruments were used: the Neuropathic Pain Symptom Inventory was used to measure the severity of CIPN; the Screening of Activity Limitation and Safety Awareness scale was used to evaluate RDA; the Profile of Mood States Short Form was used to assess negative mood; and the Functional Assessment Cancer Center Therapy‐Colorectal scale version 4 was used to evaluate QoL. Relationships among the variables were analyzed by bivariate correlation, hierarchical multiple linear regression, and Baron and Kenny's mediation testing. One hundred three colorectal adenocarcinoma patients with CIPN after receiving oxaliplatin‐based chemotherapy were enrolled. Patients had mild‐to‐moderate CIPN and mild RDA. Significant correlations were found between CIPN and mood (r = 0.425, P < 0.001), between RDA and mood (r = 0.343, P < 0.001), and between RDA and QoL (r = 0.285, P < 0.01). RDA and mood may impact QoL. Under mediation effect analysis, mood mediated 38.48% of the effect of RDA on QoL (P < 0.001). Negative mood is the major factor impacting QoL in colorectal cancer patients with CIPN. Although the management of CIPN and RDA can prevent irreversible functional problems, enhancing the adaption of mood disturbance can strongly promote their QoL.

Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy

“…Multivariable proportional odds logistic analysis indicated that malaise, edema of the limbs, peripheral sensory neuropathy, pruritus, and dry skin were significant factors for reducing the EQ-5D-5L utility value. Several reports support the present results, highlighting the association between adverse events and decreased QOL [ 8 , 19 – 21 ]. Secondary analysis using proportional odds logistic regression did not show a significant association between QOL and cancer type or anticancer drugs.…”

Qualitative Evaluation of the Influence of Acute Oxaliplatin‐Induced Peripheral Neuropathy on Quality of Life and Activities of Daily Life

“…Previous studies show that chronic CIPN does also affect QoL 15,16,19,20 . However, results of these studies cannot be translated to the influence of acute CIPN on daily QoL.…”

“…These symptoms are the main dose‐limiting toxicity of oxaliplatin 6,8,9,14 . Addressing acute oxaliplatin‐induced neuropathic complaints, given their relationship to chronic neuropathy, is of utmost importance, while OIPN in colorectal cancer survivors is associated with depressive symptoms, reduced sleep quality, and reduced health‐related QoL 15–18 …”

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

“…Although previous studies have explored these issues, most research has focused on patients with colorectal cancer [ 18 , 19 , 20 ], breast cancer [ 21 ], or those in Western countries [ 22 , 23 , 24 ]; or on other chemotherapy regimens such as taxane [ 22 , 23 ], paclitaxel [ 23 , 24 ], or carboplatin [ 23 , 24 ]. Clinical observation indicates that LC patients treated with platinum-based regimens report CIPN-related symptoms that affect daily function and QoL, and insufficient attention has been devoted to this important topic.…”